WHO Tuberculosis day 2014
March 24th 2014 marks World Tuberculosis (TB) day. This day commemorates the day in 1882 when Dr Robert Koch announced that he had discovered the cause of TB. This year’s World Health Organization (WHO) TB Day campaign focuses on the 'missed' 3 million to ensure that everyone suffering from TB has access to diagnosis, treatment and cure.
The Nuffield Department of Medicine asked Professor Helen McShane, a Wellcome Trust Senior Clinical Fellow and Professor in Vaccinology, to explain why TB is still such a huge problem and how her research developing an improved TB vaccine, is aiming to improve this situation.
Q: Why is it important to raise public awareness of TB? How many people are affected by TB each year?
Helen McShane: TB remains a very significant cause of both death and disease throughout the world. The latest WHO figures show 8.6 million new cases and 1.3 million deaths throughout the world in 2012. In addition, about one third of the world’s population (2 billion people) are estimated to be latently infected with TB. These people are at risk of reactivation of this latent TB, should they become immunocompromised for any reason. Globally the commonest cause of immunosuppression is co-infection with HIV and the geographical overlap between the HIV and TB epidemics, particularly in sub-Saharan Africa, has had a devastating impact. Interesting, the latest WHO report shows that there has been some progress in this area and that in the last 10 years TB incidence has been very slowly falling overall in the world. However, the pace of change is much too slow.
Q: Why do we need an alternative to the Bacille Calmette-Guérin (BCG) vaccine?
HM: BCG is one of the world’s most widely used vaccines. It has been given to over 3 billion people throughout the world. It was developed in 1921, almost 100 years ago, and remains the only licensed vaccine for the prevention of TB. BCG is given pretty throughout the world in infancy, as soon after birth as possible. When BCG is given at birth it does protect against disseminated disease (TB that has spread outside of the lungs), and particularly TB meningitis in children. It is very effective at doing that. What BCG is not nearly as good at is protecting against lung disease, particularly in young adults and adolescents, which is where the burden of transmission is, which is therefore responsible for fuelling the epidemic. We need a better vaccine to be given either at birth or perhaps in adolescence, when BCG is starting to wane.
Q: Can you tell us about the MVA85A vaccine?
HM:In terms of what is happening in vaccine development there are two broad strategies. Some groups are developing replacements for BCG. The idea here is that we can make BCG better. Some of that is about making BCG safer, since BCG is a live attenuated vaccine we can’t give it to people or babies who are infected with HIV. The other strategy is to develop a booster vaccine to be given at a later point in time. You would give BCG as it is and then boost later on in infancy or later on in adolescence, when we know that the effects of BCG are starting to wane. That is the strategy that most work in this field has been focusing on to date and it is the strategy that we have been focusing on here in Oxford; MVA85A is an example of a booster vaccine to be given after BCG.
Q: Can you tell us about the results from last year’s trial?
HM: We reported the results of a very large Phase IIb efficacy trial in South African babies in February last year (2013). This was a trial where all the babies received BCG at birth and then half of the babies were boosted with MVA85A at between 4 and 6 months of age. What we found was that the vaccine was safe but it stimulated relatively weak immune responses and there was no improvement in protection over BCG alone. I think this tells us many important things. One of which is that we need to design more potent vaccines, particularly in the target populations. Since that trial, the field has moved away from infant vaccination and is more focused on vaccinating adolescents as they are responsible for transmission. A vaccine that worked in adolescents would have a greater impact on the epidemic though reducing transmission. We know that the immunogenicity of MVA85A and other vaccines is better in adolescents than it is infants, so we are doing some studies at the moment in Oxford where we are looking at different routes of immunisation. One of these is immunising directly into the airways as we have some animal data that shows that this is the best way to protect against TB. This makes sense as this is how TB enters the body. We are also doing some work with other vaccines and working with other vaccine developers to combine vaccines, as it may well be that you need to combine different sorts of vaccines to induce the most potent immune response.
Q: How has our understanding of TB and future vaccine strategies improved?
HM: The real challenge in the field of TB is that we don’t know how well any of the animal models represent human disease and that is a bit of a chicken and egg situation - we won’t know how well these animal models represent human efficacy until we have a vaccine that works in humans. I think what we have learnt over the past ten years, in part from our efficacy trial and in part from other groups, is that these animal models need to be refined. There are many different groups working on this, including mine. I also think that we need better models by which we test vaccines. In other vaccine fields we use human challenge models to facilitate vaccine development. We are working in Oxford on a human BCG challenge model to see if such a model would be a useful tool in selecting promising vaccines that should go forward for further trials. The other major challenge is that we don’t have a biomarker or an immunological correlate of protection, with which we could guide vaccine design and development; so again more work is needed with that. One of the things that we are doing with the samples from the infant trial is lots of detailed immunology studies, so that we can try and understand why some children got TB and other children didn’t. If we can understand the differences in immune responses between these children then perhaps that information would steer us towards a new vaccine design..
Q: Do you think that TB will ever be eradicated in our lifetime?
HM: I think that eradication is a very big word. I believe that the reason we could eradicate other diseases, such as smallpox, is that there was no latent phase. With 2 billion people latently infected, eradication within my lifetime is not feasible. But I think if we can maintain the momentum this whole field has gained over the last ten years there is a huge amount that we can do to work towards eradicating TB. Ultimately, I would think that in the next 20 years we may have a deployable vaccine.
- Institutes, centres & units
- NDM Strategic
- Contact
- Public Involvement
-
News
- Using management thinking to fight the superbug crisis
- Getting rid of malaria possible, if we try something new, say experts
- Success for NDM project awarded Public Engagement Seed Funding
- Flu vaccine spinout secures a further £20m in funding
- Global health needs demand new approach to drug discovery
- Building international partnerships to tackle disease
- Nepali pilgrims to Gosaikunda video
- China Vice Premier in Oxford for signing of research collaboration
- Largest genetic study of mosquitoes reveals spread of insecticide resistance across Africa
- Researchers attack Mekong malaria superbug on multiple fronts
- Kevin Marsh Wins 2017 Drexel Prize in Infectious Disease
- Prof Simon Leedham wins CRUK Prize
- Oxford-Mahidol collaboration shortlisted for Newton Prize
- BioBeat unveils 2017’s 50 Movers and Shakers
- Study raises possibility of vaccines against allergies and Alzheimer’s
- Celebrating Oxfordshire brightest science stars
- New structural insights accelerate drug discovery in the ubiquitin system for cancer therapy
- National Academy of Medicine elects Nick White as international member
- New collaboration to tackle superbugs
- 115 years of malaria in Africa
- Oxford and the mosquito
- World-first trial for universal flu vaccine
- New typhoid vaccine offers hope of protection for children
- Prof Emily Chan wins the 2017 UGC Teaching Award
- The Medical Research Foundation to fund first national PhD Training Programme to tackle antimicrobial resistance
- Superbug’s spread to Vietnam threatens malaria control
- New NDM Professors
- Establishing the Africa Oxford Initiative
- Combining cultures
- Experts urge rethink of ‘outdated’ asthma categorisation
- International research network nominated for ‘Oscar of higher education’
- Oxford University claims top world ranking for second year
- Bash the Bug! Winner of 2017 NIHR Let’s Get Digital competition
- Scientists discover unknown virus in ‘throwaway’ DNA
- Improved home designs may fight malaria in Africa
- Antibodies may reveal timing of previous influenza infection
- Discovery Award to decode TB DNA
- Is it time to drop the ‘complete the course’ message for antibiotics?
- World Hepatitis Day
- Call for Abstract MVVR5 2017
- Breaking boundaries in our DNA
- Quick test can predict anaemia in malaria patients treated with artemisinins
- New Year's Honours 2018
- What's behind the sudden rise in measles deaths in Europe?
- Cancer hijacks natural cell process to survive
- Mahidol begins Asia’s first study of RTS,S malaria vaccine
- Oxford one of six sites to receive funding for health data science
- Five surprising things DNA has revealed about our ancestors
- OUMNH Exhibition based on centre research
- Could aspirin be used to treat tuberculous meningitis?
- ALS Reproducible Antibody Platform launched
- Cultural barriers to tackling the superbug crisis
- ALERRT epidemic research network launched in sub-Saharan Africa
- Making malaria visible
- Women in STM
- Female body shape gene may increase risk of type 2 diabetes
- The town that breeds resistance to Malaria drugs
- Can you cure HIV?
- Professor Dominic Kwiatkowski joins the Fellowship of the Royal Society
- Prof Vincenzo Cerundolo elected Fellow of the Royal Society
- NDM Researchers elected as Fellows of the Academy of Medical Science
- Using management thinking to fight the superbug crisis
- FORMA Therapeutics and the University of Oxford Announce Multi-Year Cross-Border Collaboration
- HIV researchers create Chelsea garden to raise awareness of disease stigma
- China Vice Premier and Minster of National Health Commission visit to CTI Beijing
- Oxford overtakes Cambridge for first time in QS world rankings
- New age-based regimen for single low-dose primaquine to block malaria transmission
- Rosalind Franklin Institute will 'transform' life sciences research through disruptive technologies
- Big Data Institute wins a 2018 RIBA South Award
- NDM Researcher gets £1m boost to study immunology of asthma
- Professor Rose McGready awarded Alumni Award for Service to Humanity
- Researchers explore malaria vaccines and antibiotic resistance at RS Summer Science Exhibition
- Trial of ‘kick and kill’ approach to HIV cure leaves puzzles to be solved
- NDM Researcher recognised for major contribution in clinical sciences
- ASHG Honours Professor Cecilia Lindgren with Mentorship Award
- New NDM Professors
- Prof Helen McShane appointed as new Director of Oxford Biomedical Research Centre
- Detailed map of colon cells in health and disease
- UK-led study marks shift towards genetic era in tackling TB
- Tales of treatment, of modernity and tradition, and of global health crisis
- Faith Osier TED talk
- 'Tantalising and exciting’: UK Biobank genetics opens the door to a new era of health research
- Oxford secures £17.5 million to lead national programmes in AI to improve healthcare
- New grant to study the role of immune cells in lung regeneration
- Dr Ross Chapman welcomed as EMBO Young Investigator
- New vaccines centre to protect UK from pandemic threats
- Professor Sir David Weatherall: 1933-2018
- Congratulations to Jeremy Farrar, knighted in the New Year's Honours 2019
- Watch Prof Peter Donnelly speak at Royal Society AI event
- NDM's Translational Gastroenterology Unit awarded a CRUK Primer grant of £100,000
- ISARIC awarded £4.5 million to tackle the global threat of epidemic infectious diseases
- Tracking resistance results presented at Westminster
- The battle within- new animation on the immune system
- Vaccine developed to treat osteoarthritic pain
- World Malaria Day 2019
- Faces of malaria
- Mads Gyrd-Hansen awarded Wellcome Trust Senior Research Fellowship renewal
- NDM Researchers elected Fellows of the Academy of Medical Sciences
- Oxford academics recognised in 2019 Queen’s Birthday Honours
- Ross Chapman awarded 2019 Lister Prize
- New maps could show how to beat malaria
- Vice-Chancellor’s Choice Award for Public Engagement with Research
- New malaria parasite mutations cause alarming antimalarial drug failures in Southeast Asia
- New NDM Professors
- The RECOVERY Trial has recruited 1000 patients in 15 days
- Controlling coronavirus transmission using a mobile app to trace close proximity contacts
- Digital contact tracing can slow or even stop coronavirus transmission and ease us out of lockdown
- Oxford's COVID-19 research receives government funding
- First patients enrolled in new clinical trial of possible COVID-19 treatments
- Covid-19: how effective is social distancing?
- Infectious disease experts provide evidence for a coronavirus mobile app for instant contact tracing
- Sir Peter Ratcliffe on BBC Radio 4 - The Life Scientific
- Wellcome Investigator Awards
- International research consortium activates clinical study for novel coronavirus in England and Scotland
- Professor Vincenzo Cerundolo FRS 1959-2020
- Oxford University awarded €56 million in European Research Council funding
- Oxford named best for medicine for ninth consecutive year
- NDM DPhil Graduate Student Prizes 2019
- Modelling research aims to inform new WHO roadmap for neglected tropical diseases
- Woman of the Future award for Science
- Obesity now linked to broader range of leading killers, with women and men showing different patterns of risk
- Medical Sciences and climate breakdown: time to move beyond evidence
- Oxford Tropical Medicine awarded two RSTMH medals
- Oxford ranked world’s best university for fourth year running
- Landmark partnership announced for development of COVID-19 vaccine
- Chan Zuckerberg Initiative awards funding to Oxford team to support inflammation research
- Oxford University Coronavirus Research Webinar
- New study reveals Oxford coronavirus vaccine produces strong immune response
- The Duke of Cambridge visits Oxford Vaccine Centre
- The Ludwig Institute for Cancer Research welcomes cancer epigenetics researcher Yang Shi
- New NDM titles awarded
- Future of Oxford professorship in vaccinology secured with £3.5 million gift
- Oxford study suggests notable decline in coronavirus cases and R rate on Isle of Wight after launch of the test and trace programme
- Dave Stuart awarded The Gabor Medal 2020
- Latest version of COVID-19 contact tracing app ready for testing on the Isle of Wight and Newham, London
- Collaboration with Magdalen College outreach to run remote work experience
- Persistent immune memory of COVID-19 found in recovered patient T cells
- New research shows tracing apps can save lives at all levels of uptake
- Evaluation of LamPORE rapid tests for Covid-19 show high levels of diagnostic sensitivity
- Comparison of five tests used to detect COVID-19 antibodies shows Siemens and Oxford assays met regulatory targets
- Oxford’s OpenABM-Covid19 mathematical model helps to control the coronavirus epidemic
- Oxford’s OpenABM-Covid19 mathematical model helps to control the coronavirus epidemic
- The University of Oxford and King Abdulaziz University (KAU) have partnered to create a new Centre for Artificial Intelligence and Precision Medicine.
- Professor Sarah Walker, a Professor of Medical Statistics and Epidemiology in NDM and the Oxford BRC’s Co-theme Lead for Antimicrobial Resistance and Modernising Microbiology, is to receive an OBE.
- Simon Leedham appointed as Professor of Molecular and Population Genetics
- Two vital research programmes taking place at the university of Oxford may hold the key to understanding the immunity of recovered Covid-19 patients.
- New partnership with The Alan Turing Institute and Royal Statistical Society to support Joint Biosecurity Centre COVID-19 response
- NDM’s Jenner Institute appoints first Bvlgari Scholars
- NDM New Professors
- Trials of Oxford coronavirus vaccine begin in Kenya
- Oxford ramps up COVID-19 testing capability
- Oxford’s vaccine research and development boosted by donation from Wafic Saïd
- Oxfordshire Young Scientists of the Year 2020
- Oxford University breakthrough on global COVID-19 vaccine
- First peer-reviewed results of phase 3 human trials of Oxford coronavirus vaccine demonstrate efficacy
- Statement from the Chief Investigators of the Randomised Evaluation of COVid-19 thERapY (RECOVERY) Trial on azithromycin, 14 December 2020
- National COVID-19 Infections Survey reveals changes to pandemic over time
- Professor Susie Dunachie awarded flagship NIHR career development award
- Oxford University welcomes UK regulatory emergency use authorisation of coronavirus vaccine
- Professor Sir Dave Stuart, FRS FMedSci knighted in New Year's Honours
- National consortium to study threats of new SARS-CoV-2 variants
- Lateral flow devices detect most infectious COVID-19 cases and could allow a safer relaxation of the current lockdown
- Work for us